{"id":240161,"date":"2026-09-10T11:10:46","date_gmt":"2026-09-10T05:40:46","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=240161"},"modified":"2026-09-10T11:10:46","modified_gmt":"2026-09-10T05:40:46","slug":"emcure-pharmaceuticals-q2-results-fy27-preview-date-expectations","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-q2-results-fy27-preview-date-expectations\/","title":{"rendered":"Emcure Pharmaceuticals Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Emcure Pharmaceuticals share price Rs 1,914.40 on 9 September 2026, down 0.59%. Q2 FY27 results date not confirmed. Q1 FY27 net profit Rs 292.00 crore. Q2 FY26 base a profit of Rs 251.00 crore.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The Emcure Pharmaceuticals Q2 results date for FY27 is not confirmed, and Emcure Pharmaceuticals Ltd. had not filed a board meeting intimation with the NSE or BSE as of 9 September 2026. Indian listing rules require the September 2026 quarter results to be published within 45 days of the quarter end, an outer deadline of 14 November 2026. The quarter will be measured against a September 2025 base of Rs 2,270.00 crore in revenue and a profit of Rs 251.00 crore. This preview uses reported actuals only and carries no estimated revenue or profit figure for the coming quarter.<\/p>\n<\/p><\/div>\n<p>The Emcure Pharmaceuticals Q2 results FY27 announcement is the next scheduled earnings event for <a href=\"https:\/\/univest.in\/stocks\/emcure\/emcure-pharmaceuticals-ltd-share-price-today\">Emcure Pharmaceuticals Ltd.<\/a>, a pharmaceutical company making and selling branded generics, injectables and biosimilars for the Indian market and for export. The stock traded at Rs 1,914.40 on the NSE on 9 September 2026, down 0.59% from the previous close of Rs 1,925.80, about 6.5% below its 52-week high of Rs 2,048.00 and 51.9% above its 52-week low of Rs 1,260.00.<\/p>\n<p>What makes the Emcure Pharmaceuticals Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 2,270.00 crore of revenue and a profit of Rs 251.00 crore, while the most recent quarter on record, Q1 FY27, produced Rs 2,580.00 crore and a profit of Rs 292.00 crore. Everything below is built from those reported figures rather than from any forecast.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=emcure_q2_fy27\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#When_Is_the_Emcure_Pharmaceuticals_Q2_Results_FY27_Date\" title=\"When Is the Emcure Pharmaceuticals Q2 Results FY27 Date?\">When Is the Emcure Pharmaceuticals Q2 Results FY27 Date?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Emcure_Pharmaceuticals_Q2_Results_Expectations_What_the_Market_Is_Actually_Tracking\" title=\"Emcure Pharmaceuticals Q2 Results Expectations: What the Market Is Actually Tracking\">Emcure Pharmaceuticals Q2 Results Expectations: What the Market Is Actually Tracking<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Emcure_Pharmaceuticals_Q2_Results_Preview_The_Q1_FY27_Actuals_It_Builds_On\" title=\"Emcure Pharmaceuticals Q2 Results Preview: The Q1 FY27 Actuals It Builds On\">Emcure Pharmaceuticals Q2 Results Preview: The Q1 FY27 Actuals It Builds On<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Q2_FY26_Base_The_Comparison_Emcure_Pharmaceuticals_Q2_Results_FY27_Must_Beat\" title=\"Q2 FY26 Base: The Comparison Emcure Pharmaceuticals Q2 Results FY27 Must Beat\">Q2 FY26 Base: The Comparison Emcure Pharmaceuticals Q2 Results FY27 Must Beat<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Emcure_Pharmaceuticals_Quarterly_Results_Trend_Over_the_Last_Four_Quarters\" title=\"Emcure Pharmaceuticals Quarterly Results Trend Over the Last Four Quarters\">Emcure Pharmaceuticals Quarterly Results Trend Over the Last Four Quarters<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Key_Factors_That_Could_Shape_Emcure_Pharmaceuticals_Q2_Results_FY27\" title=\"Key Factors That Could Shape Emcure Pharmaceuticals Q2 Results FY27\">Key Factors That Could Shape Emcure Pharmaceuticals Q2 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Domestic_Brands_Against_Exports\" title=\"Domestic Brands Against Exports\">Domestic Brands Against Exports<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Interest_Cost_Is_Rising\" title=\"Interest Cost Is Rising\">Interest Cost Is Rising<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Consistent_Returns_at_a_Full_Multiple\" title=\"Consistent Returns at a Full Multiple\">Consistent Returns at a Full Multiple<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Emcure_Pharmaceuticals_Q2_Results_FY27_Share_Price_and_Valuation_Going_Into_the_Print\" title=\"Emcure Pharmaceuticals Q2 Results FY27: Share Price and Valuation Going Into the Print\">Emcure Pharmaceuticals Q2 Results FY27: Share Price and Valuation Going Into the Print<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#What_Investors_Should_Watch_When_Emcure_Pharmaceuticals_Q2_Results_Are_Announced\" title=\"What Investors Should Watch When Emcure Pharmaceuticals Q2 Results Are Announced\">What Investors Should Watch When Emcure Pharmaceuticals Q2 Results Are Announced<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Conclusion_on_Emcure_Pharmaceuticals_Q2_Results_FY27\" title=\"Conclusion on Emcure Pharmaceuticals Q2 Results FY27\">Conclusion on Emcure Pharmaceuticals Q2 Results FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#FAQs_on_Emcure_Pharmaceuticals_Q2_Results_FY27\" title=\"FAQs on Emcure Pharmaceuticals Q2 Results FY27\">FAQs on Emcure Pharmaceuticals Q2 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#What_is_the_Emcure_Pharmaceuticals_Q2_results_date_for_FY27\" title=\"What is the Emcure Pharmaceuticals Q2 results date for FY27?\">What is the Emcure Pharmaceuticals Q2 results date for FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#What_quarter_do_the_Emcure_Pharmaceuticals_Q2_results_2026_cover\" title=\"What quarter do the Emcure Pharmaceuticals Q2 results 2026 cover?\">What quarter do the Emcure Pharmaceuticals Q2 results 2026 cover?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#What_were_the_Emcure_Pharmaceuticals_Q1_FY27_results\" title=\"What were the Emcure Pharmaceuticals Q1 FY27 results?\">What were the Emcure Pharmaceuticals Q1 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#What_were_Emcure_Pharmaceuticals_Q2_FY26_results_in_the_September_2025_quarter\" title=\"What were Emcure Pharmaceuticals Q2 FY26 results in the September 2025 quarter?\">What were Emcure Pharmaceuticals Q2 FY26 results in the September 2025 quarter?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#What_are_the_main_Emcure_Pharmaceuticals_Q2_results_expectations_this_quarter\" title=\"What are the main Emcure Pharmaceuticals Q2 results expectations this quarter?\">What are the main Emcure Pharmaceuticals Q2 results expectations this quarter?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#What_is_Emcure_Pharmaceuticals_share_price_today_ahead_of_the_Q2_earnings\" title=\"What is Emcure Pharmaceuticals share price today ahead of the Q2 earnings?\">What is Emcure Pharmaceuticals share price today ahead of the Q2 earnings?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Is_Emcure_Pharmaceuticals_a_good_stock_to_buy_before_the_Q2_results\" title=\"Is Emcure Pharmaceuticals a good stock to buy before the Q2 results?\">Is Emcure Pharmaceuticals a good stock to buy before the Q2 results?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"When_Is_the_Emcure_Pharmaceuticals_Q2_Results_FY27_Date\"><\/span><strong>When Is the Emcure Pharmaceuticals Q2 Results FY27 Date?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Emcure Pharmaceuticals Q2 results date for FY27 is not confirmed. As of 9 September 2026, Emcure Pharmaceuticals Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.<\/p>\n<p>What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Emcure Pharmaceuticals Q2 results date becomes public through that filing rather than through any advance announcement.<\/p>\n<p>The Emcure Pharmaceuticals Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Emcure Pharmaceuticals.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Emcure_Pharmaceuticals_Q2_Results_Expectations_What_the_Market_Is_Actually_Tracking\"><\/span><strong>Emcure Pharmaceuticals Q2 Results Expectations: What the Market Is Actually Tracking<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>No verified analyst estimate for the Emcure Pharmaceuticals Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Emcure Pharmaceuticals. The Emcure Pharmaceuticals Q2 results watchlist below is built from what the company has actually reported and disclosed.<\/p>\n<p>The first is revenue, which rose in every one of the five quarters from Rs 2,101 crore to Rs 2,580 crore. The September 2025 base of Rs 2,270 crore is about 12% below the most recent quarter.<\/p>\n<p>The second is the operating margin, which was 21% in both September 2025 and Q1 FY27 and stayed inside a 19% to 21% band throughout. Operating profit rose from Rs 475 crore to Rs 532 crore over the same period.<\/p>\n<p>The third is other income, which was negative Rs 36 crore in December 2025 against Rs 0 crore to Rs 14 crore in the other four quarters. That single line cut pre-tax profit to Rs 314 crore in a quarter whose operating profit was the second highest of the five.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check Emcure Pharmaceuticals Ltd. Live Fundamentals on the Univest Screener<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Emcure_Pharmaceuticals_Q2_Results_Preview_The_Q1_FY27_Actuals_It_Builds_On\"><\/span><strong>Emcure Pharmaceuticals Q2 Results Preview: The Q1 FY27 Actuals It Builds On<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Emcure Pharmaceuticals Ltd. reported revenue of Rs 2,580.00 crore in Q1 FY27, up 22.80% from Rs 2,101.00 crore in Q1 FY26, and a profit of Rs 292.00 crore at the net level, up 35.81% from Rs 215.00 crore in Q1 FY26. These are reported actuals, not estimates.<\/p>\n<p>Sequentially, revenue was up 4.45% over the March 2026 quarter figure of Rs 2,470.00 crore, and net profit was up 19.67% from Rs 244.00 crore in Q4 FY26. Operating margin stood at 21% in Q1 FY27 against 21% in the September 2025 quarter, which is the comparison the Emcure Pharmaceuticals Q2 results print will be read against.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Q2_FY26_Base_The_Comparison_Emcure_Pharmaceuticals_Q2_Results_FY27_Must_Beat\"><\/span><strong>Q2 FY26 Base: The Comparison Emcure Pharmaceuticals Q2 Results FY27 Must Beat<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Emcure Pharmaceuticals Ltd. reported revenue of Rs 2,270.00 crore and a profit of Rs 251.00 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Emcure Pharmaceuticals Q2 results preview.<\/p>\n<p>Net profit in that base quarter was below the Rs 292.00 crore just reported for Q1 FY27, so the year-on-year comparison starts from a manageable level. Revenue of Rs 2,270.00 crore sits below the Rs 2,580.00 crore of the June 2026 quarter, which frames how much sequential movement the Emcure Pharmaceuticals Q2 results print needs to show growth.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Emcure_Pharmaceuticals_Quarterly_Results_Trend_Over_the_Last_Four_Quarters\"><\/span><strong>Emcure Pharmaceuticals Quarterly Results Trend Over the Last Four Quarters<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Quarter<\/th>\n<th>Revenue (Rs Cr)<\/th>\n<th>Net Profit (Rs Cr)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Q2 FY26 (Sep 2025)<\/td>\n<td>2,270.00<\/td>\n<td>251.00<\/td>\n<\/tr>\n<tr>\n<td>Q3 FY26 (Dec 2025)<\/td>\n<td>2,363.00<\/td>\n<td>231.00<\/td>\n<\/tr>\n<tr>\n<td>Q4 FY26 (Mar 2026)<\/td>\n<td>2,470.00<\/td>\n<td>244.00<\/td>\n<\/tr>\n<tr>\n<td>Q1 FY27 (Jun 2026)<\/td>\n<td>2,580.00<\/td>\n<td>292.00<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company&#8217;s exchange filings, and they are the only basis this Emcure Pharmaceuticals Q2 results preview uses.<\/p>\n<p>Revenue across those four quarters ranged from Rs 2,270.00 crore to Rs 2,580.00 crore, and net profit from Rs 231.00 crore to Rs 292.00 crore. That spread is the honest context for the Emcure Pharmaceuticals Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Factors_That_Could_Shape_Emcure_Pharmaceuticals_Q2_Results_FY27\"><\/span><strong>Key Factors That Could Shape Emcure Pharmaceuticals Q2 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Emcure Pharmaceuticals Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Emcure Pharmaceuticals has already reported.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Domestic_Brands_Against_Exports\"><\/span><strong>Domestic Brands Against Exports<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Branded generics sold in India carry different economics from regulated market exports and from the injectables and biosimilars business. The therapy and geography mix disclosed with the results explains the margin more precisely than the revenue figure does.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Interest_Cost_Is_Rising\"><\/span><strong>Interest Cost Is Rising<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Borrowings rose from about Rs 1,023 crore in March 2025 to Rs 1,521 crore in March 2026, roughly 49% in a year, and quarterly interest went from Rs 27 crore to Rs 46 crore across the five quarters. That climb is worth watching against a steady operating margin.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Consistent_Returns_at_a_Full_Multiple\"><\/span><strong>Consistent Returns at a Full Multiple<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Return on equity stands at 20.10% with a debt to equity ratio of 0.31. The stock trades at a price to earnings ratio of 35.29 and a price to book ratio of 7.33, above both its 50-day average of Rs 1,887.43 and its 200-day average of Rs 1,640.57.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Emcure_Pharmaceuticals_Q2_Results_FY27_Share_Price_and_Valuation_Going_Into_the_Print\"><\/span><strong>Emcure Pharmaceuticals Q2 Results FY27: Share Price and Valuation Going Into the Print<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Emcure Pharmaceuticals share price today is Rs 1,914.40 on the NSE, down Rs 11.40 or 0.59% from the previous close of Rs 1,925.80 on 9 September 2026, ahead of the Emcure Pharmaceuticals Q2 results announcement.<\/p>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Value (9 September 2026)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>NSE Symbol<\/td>\n<td>EMCURE<\/td>\n<\/tr>\n<tr>\n<td>Current Market Price<\/td>\n<td>Rs 1,914.40<\/td>\n<\/tr>\n<tr>\n<td>52-Week High<\/td>\n<td>Rs 2,048.00<\/td>\n<\/tr>\n<tr>\n<td>52-Week Low<\/td>\n<td>Rs 1,260.00<\/td>\n<\/tr>\n<tr>\n<td>Market Capitalisation<\/td>\n<td>Rs 36,306 crore<\/td>\n<\/tr>\n<tr>\n<td>PE Ratio<\/td>\n<td>35.29<\/td>\n<\/tr>\n<tr>\n<td>PB Ratio<\/td>\n<td>7.33<\/td>\n<\/tr>\n<tr>\n<td>EPS (TTM)<\/td>\n<td>Rs 54.25<\/td>\n<\/tr>\n<tr>\n<td>Book Value per Share<\/td>\n<td>Rs 261.00<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.31<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity<\/td>\n<td>20.10%<\/td>\n<\/tr>\n<tr>\n<td>50-Day Moving Average<\/td>\n<td>Rs 1,887.43<\/td>\n<\/tr>\n<tr>\n<td>200-Day Moving Average<\/td>\n<td>Rs 1,640.57<\/td>\n<\/tr>\n<tr>\n<td>RSI (14)<\/td>\n<td>57.28<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The stock trades above both its 50-day average of Rs 1,887.43 and its 200-day average of Rs 1,640.57, with a 14-day RSI of 57.28. None of this is a view on where the shares go once the Emcure Pharmaceuticals Q2 results are announced, and no price target is offered here.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Emcure Pharmaceuticals Ltd. live price and quarterly earnings updates.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Investors_Should_Watch_When_Emcure_Pharmaceuticals_Q2_Results_Are_Announced\"><\/span><strong>What Investors Should Watch When Emcure Pharmaceuticals Q2 Results Are Announced<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Four lines carry most of the information in a company of this size, and reading them in order keeps the Emcure Pharmaceuticals Q2 results print in proportion.<\/p>\n<ol>\n<li>Revenue against the Rs 2,270.00 crore reported in the September 2025 base quarter<\/li>\n<li>Net profit against a profit of Rs 251.00 crore in that same quarter<\/li>\n<li>Operating margin against 21% in Q1 FY27<\/li>\n<li>Any exceptional item, provision or one-off gain disclosed alongside the numbers<\/li>\n<\/ol>\n<p>A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Emcure Pharmaceuticals Q2 results announcement should be read together with the notes to the results rather than the headline alone.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion_on_Emcure_Pharmaceuticals_Q2_Results_FY27\"><\/span><strong>Conclusion on Emcure Pharmaceuticals Q2 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Emcure Pharmaceuticals Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Emcure Pharmaceuticals Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.<\/p>\n<p>On that basis the Emcure Pharmaceuticals Q2 results FY27 print faces a base of Rs 2,270.00 crore in revenue and a profit of Rs 251.00 crore, with the most recent quarter having delivered Rs 2,580.00 crore and a profit of Rs 292.00 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Emcure Pharmaceuticals, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Emcure_Pharmaceuticals_Q2_Results_FY27\"><\/span><strong>FAQs on Emcure Pharmaceuticals Q2 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Emcure_Pharmaceuticals_Q2_results_date_for_FY27\"><\/span><strong>What is the Emcure Pharmaceuticals Q2 results date for FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Emcure Pharmaceuticals Q2 results date for FY27 is not confirmed. Emcure Pharmaceuticals Ltd. had not filed a board meeting intimation with the NSE or BSE as of 9 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_quarter_do_the_Emcure_Pharmaceuticals_Q2_results_2026_cover\"><\/span><strong>What quarter do the Emcure Pharmaceuticals Q2 results 2026 cover?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Emcure Pharmaceuticals Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Emcure Pharmaceuticals Ltd. reports revenue, operating profit and net profit for that period, and the Emcure Pharmaceuticals Q2 results filing also carries the notes to the accounts.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_the_Emcure_Pharmaceuticals_Q1_FY27_results\"><\/span><strong>What were the Emcure Pharmaceuticals Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Emcure Pharmaceuticals Ltd. reported revenue of Rs 2,580.00 crore in Q1 FY27 and a profit of Rs 292.00 crore at the net level. Revenue was up 22.80% versus Q1 FY26 and net profit was up 35.81% from Rs 215.00 crore in Q1 FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_Emcure_Pharmaceuticals_Q2_FY26_results_in_the_September_2025_quarter\"><\/span><strong>What were Emcure Pharmaceuticals Q2 FY26 results in the September 2025 quarter?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Emcure Pharmaceuticals Ltd. reported revenue of Rs 2,270.00 crore and a profit of Rs 251.00 crore in Q2 FY26. Operating margin was 21%. Those figures form the base for the Emcure Pharmaceuticals Q2 results FY27 comparison.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_Emcure_Pharmaceuticals_Q2_results_expectations_this_quarter\"><\/span><strong>What are the main Emcure Pharmaceuticals Q2 results expectations this quarter?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No verified analyst estimate is publicly available. The Emcure Pharmaceuticals Q2 results expectations centre on revenue against the Rs 2,270.00 crore base, net profit against a profit of Rs 251.00 crore, operating margin against 21% in Q1 FY27, and any exceptional item disclosed with the numbers.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Emcure_Pharmaceuticals_share_price_today_ahead_of_the_Q2_earnings\"><\/span><strong>What is Emcure Pharmaceuticals share price today ahead of the Q2 earnings?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Emcure Pharmaceuticals share price is Rs 1,914.40 on the NSE as of 9 September 2026, down 0.59% from Rs 1,925.80. The stock is about 6.5% below its 52-week high of Rs 2,048.00 and 51.9% above its 52-week low of Rs 1,260.00, at a market capitalisation of Rs 36,306 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Emcure_Pharmaceuticals_a_good_stock_to_buy_before_the_Q2_results\"><\/span><strong>Is Emcure Pharmaceuticals a good stock to buy before the Q2 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This article does not offer a buy, sell or hold recommendation on Emcure Pharmaceuticals Ltd. The stock trades at a price-to-book ratio of 7.33 with a return on equity of 20.10%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the Emcure Pharmaceuticals Q2 results date for FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Emcure Pharmaceuticals Q2 results date for FY27 is not confirmed. Emcure Pharmaceuticals Ltd. had not filed a board meeting intimation with the NSE or BSE as of 9 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.\"}},{\"@type\":\"Question\",\"name\":\"What quarter do the Emcure Pharmaceuticals Q2 results 2026 cover?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Emcure Pharmaceuticals Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Emcure Pharmaceuticals Ltd. reports revenue, operating profit and net profit for that period, and the Emcure Pharmaceuticals Q2 results filing also carries the notes to the accounts.\"}},{\"@type\":\"Question\",\"name\":\"What were the Emcure Pharmaceuticals Q1 FY27 results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Emcure Pharmaceuticals Ltd. reported revenue of Rs 2,580.00 crore in Q1 FY27 and a profit of Rs 292.00 crore at the net level. Revenue was up 22.80% versus Q1 FY26 and net profit was up 35.81% from Rs 215.00 crore in Q1 FY26.\"}},{\"@type\":\"Question\",\"name\":\"What were Emcure Pharmaceuticals Q2 FY26 results in the September 2025 quarter?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Emcure Pharmaceuticals Ltd. reported revenue of Rs 2,270.00 crore and a profit of Rs 251.00 crore in Q2 FY26. Operating margin was 21%. Those figures form the base for the Emcure Pharmaceuticals Q2 results FY27 comparison.\"}},{\"@type\":\"Question\",\"name\":\"What are the main Emcure Pharmaceuticals Q2 results expectations this quarter?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No verified analyst estimate is publicly available. The Emcure Pharmaceuticals Q2 results expectations centre on revenue against the Rs 2,270.00 crore base, net profit against a profit of Rs 251.00 crore, operating margin against 21% in Q1 FY27, and any exceptional item disclosed with the numbers.\"}},{\"@type\":\"Question\",\"name\":\"What is Emcure Pharmaceuticals share price today ahead of the Q2 earnings?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Emcure Pharmaceuticals share price is Rs 1,914.40 on the NSE as of 9 September 2026, down 0.59% from Rs 1,925.80. The stock is about 6.5% below its 52-week high of Rs 2,048.00 and 51.9% above its 52-week low of Rs 1,260.00, at a market capitalisation of Rs 36,306 crore.\"}},{\"@type\":\"Question\",\"name\":\"Is Emcure Pharmaceuticals a good stock to buy before the Q2 results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This article does not offer a buy, sell or hold recommendation on Emcure Pharmaceuticals Ltd. The stock trades at a price-to-book ratio of 7.33 with a return on equity of 20.10%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Emcure Pharmaceuticals Q2 results FY27 date is not yet confirmed by the exchanges. Here is the September 2026 quarter watchlist for Emcure Pharmaceuticals Ltd., built on actual Q1 FY27 and Q2 FY26 numbers with no invented estimates.<\/p>\n","protected":false},"author":29,"featured_media":240160,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5331],"tags":[],"class_list":["post-240161","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-https-univest-in-blogs-category-results"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["240160"],"rank_math_title":["Emcure Pharmaceuticals Q2 FY27: Date and Outlook"],"rank_math_description":["Emcure Pharmaceuticals Q2 results FY27 preview: results date status, key expectations, Q1 FY27 and Q2 FY26 actuals plus valuation before the September 2026 print."],"rank_math_focus_keyword":["Emcure Pharmaceuticals Q2 results"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/09\/emcure-pharmaceuticals-q2-results-fy27-preview-date-expectations.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/240161","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=240161"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/240161\/revisions"}],"predecessor-version":[{"id":240162,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/240161\/revisions\/240162"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/240160"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=240161"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=240161"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=240161"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}